Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26110049 | 0.87 | FOLH1 (0.47) | FOLH1ALDH1A1ALOX15TSHRKAT2B | |
| SCHEMBL25408242 | 0.86 | FOLH1 (0.58) | FOLH1ALDH1A1ALOX15TSHRTP53 | |
| SCHEMBL28314204 | 0.85 | KAT2B (0.38) | FOLH1ALDH1A1ALOX15TSHRKAT2B | |
| SCHEMBL15763694 | 0.84 | KAT2B (0.40) | ALDH1A1KAT2BKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL14699642 | 0.84 | KAT2B (0.40) | FOLH1ALDH1A1ALOX15TSHRKAT2B | |
| Hydrochloric Acid SCHEMBL29790654 | 0.83 | KDM4E (0.40) | ALDH1A1TSHRKAT2BGAAKDM4E | |
| SCHEMBL28528967 | 0.81 | FOLH1 (0.53) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL16588078 | 0.81 | CTSD (0.46) | ALDH1A1KAT2BGAACA1CA2 | |
| SCHEMBL10425173 | 0.81 | FOLH1 (0.59) | FOLH1ALDH1A1ALOX15TSHRTP53 | |
| SCHEMBL15353860 | 0.80 | ALDH1A1 (0.53) | ALDH1A1ALOX15TSHRHTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250340580-A1 | TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS | INST NAT RECH SCIENT (CA) | 2025-11-06 | — | — | US | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| WO-2025067481-A1 | PHOSPHOLIPID DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREFOR | 上海弼领生物技术有限公司 | 2025-04-03 | — | — | WO | claimed |
| WO-2024222960-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | 上海弼领生物技术有限公司 | 2024-10-31 | — | — | WO | claimed |
| EP-4431116-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2024-09-18 | — | — | EP | claimed |
| CN-118284435-A | Drug conjugate based on epsilon-poly-L-lysine, intermediate and application thereof | 上海弼领生物技术有限公司 | 2024-07-02 | — | — | CN | claimed |
| WO-2023078464-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 上海弼领生物技术有限公司 | 2023-05-11 | — | — | WO | claimed |
| US-20230099200-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2023-03-30 | — | — | US | claimed |
| EP-4081263-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) | 2022-11-02 | — | — | EP | claimed |
| US-20220227801-A1 | TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS | INSTITUT NATIONAL DE LA RECHERCHE EN SCIENTIFIQUE (CA) | 2022-07-21 | — | — | US | claimed |
| EP-4007763-A1 | TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS | Institut National de la Recherche Scientifique (CA) | 2022-06-08 | — | — | EP | claimed |
| WO-2021130329-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2021-07-01 | — | — | WO | claimed |
| WO-2020243815-A1 | TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2020-12-10 | — | — | WO | claimed |
| CN-110003185-B | Macrocyclic polyamine amphiphilic compound based on green fluorescent protein chromophore BI and preparation method and application thereof | 北京师范大学 | 2020-05-19 | — | — | CN | claimed |
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-4234566-B1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI SHENZHEN (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20090233280-A1 | METHOD OF ACQUIRING INFORMATION REGARDING BASE SEQUENCE AND INFORMATION READING DEVICE FOR THE SAME | CANON KABUSHIKI KAISHA (JP) | 2009-09-17 | — | — | US | disclosed |
| WO-2007077952-A1 | METHOD AND DEVICE FOR DETERMINING A NUCLEIC ACID ALLELE OR BASE SEQUENCE | CANON KABUSHIKI KAISHA (JP) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340580-A1 | TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS | NEU1, NEU4, NEU3 | FOLH1 2966/4885ALDH1A1 3754/4885ALOX15 2393/4885 |
| US-20230099200-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | CXCR4, ACKR3, CXCL12 | FOLH1 75/4885ALDH1A1 3650/4885ALOX15 4040/4885 |
| US-20220227801-A1 | TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERS | NEU1, NEU3, NEU4 | FOLH1 2741/4885ALDH1A1 3702/4885ALOX15 2379/4885 |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SLC7A1, KARS1, LNPEP | FOLH1 347/4885ALDH1A1 1045/4885ALOX15 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.